Literature DB >> 29844632

Bioinformatics analysis of single and multi-hybrid epitopes of GRA-1, GRA-4, GRA-6 and GRA-7 proteins to improve DNA vaccine design against Toxoplasma gondii.

Minoo Shaddel1, Mansour Ebrahimi1,2, Mohammad Reza Tabandeh3.   

Abstract

Toxoplasma gondii, is a causative agent of morbidity and mortality in immunocompromised and congenitally-infected individuals. Attempts to construct DNA vaccines against T. gondii using surface proteins are increasing. The dense granule antigens are highly expressed in the acute and chronic phases of T. gondii infection and considered as suitable DNA vaccine candidates to control toxoplasmosis. In the present study, bioinformatics tools and online software were used to predict, analyze and compare the structural, physical and chemical characters and immunogenicity of the GRA-1, GRA-4, GRA-6 and GRA-7 proteins. Sequence alignment results indicated that the GRA-1, GRA-4, GRA-6 and GRA-7 proteins had low similarity. The secondary structure prediction demonstrated that among the four proteins, GRA-1 and GRA-6 had similar secondary structure except for a little discrepancy. Hydrophilicity/hydrophobicity analysis showed multiple hydrophilic regions and some classical high hydrophilic domains for each protein sequence. Immunogenic epitope prediction results demonstrated that the GRA-1 and GRA-4 epitopes were stable and GRA-4 showed the highest degree of antigenicity. Although the GRA-7 epitope had the highest score of immunogenicity, this epitope was instable and had the lowest degree of antigenicity and half-time in eukaryotic cell. Also, the results indicated that GRA4-GRA7 epitope and GRA6-GRA7 had the highest degree of antigenicity and immunogenicity among multi-hybrid epitopes, respectively. Totally, in the present study, single epitopes showed the highest degree of antigenicity compared with multi-hybrid epitopes. Given the results, it can be concluded that GRA-4 and GRA-7 can be powerful DNA vaccine candidates against T. gondii.

Entities:  

Keywords:  Bioinformatics analysis; DNA vaccine; GRA proteins; Toxoplasma gondii

Year:  2018        PMID: 29844632      PMCID: PMC5962505          DOI: 10.1007/s12639-018-0996-9

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  33 in total

1.  New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites.

Authors:  J M Parker; D Guo; R S Hodges
Journal:  Biochemistry       Date:  1986-09-23       Impact factor: 3.162

2.  Identification of two alleles in the GRA4 locus of Toxoplasma gondii determining a differential epitope which allows discrimination of type I versus type II and III strains.

Authors:  R Meisel; S Stachelhaus; M N Mévélec; G Reichmann; J F Dubremetz; H G Fischer
Journal:  Mol Biochem Parasitol       Date:  1996-10-30       Impact factor: 1.759

3.  Evaluation of a recombinant multiepitope peptide for serodiagnosis of Toxoplasma gondii infection.

Authors:  Jianfang Dai; Min Jiang; Yanyun Wang; Lili Qu; Rujun Gong; Jin Si
Journal:  Clin Vaccine Immunol       Date:  2012-01-04

4.  Bioinformatics analysis and expression of a novel protein ROP48 in Toxoplasma gondii.

Authors:  Jian Zhou; Lin Wang; Aihua Zhou; Gang Lu; Qihang Li; Zhilin Wang; Meiyan Zhu; Huaiyu Zhou; Hua Cong; Shenyi He
Journal:  Acta Parasitol       Date:  2016-03       Impact factor: 1.440

5.  Identification of novel B cell epitopes within Toxoplasma gondii GRA1.

Authors:  Yanhua Wang; Guangxiang Wang; Delin Zhang; Hong Yin; Meng Wang
Journal:  Exp Parasitol       Date:  2013-10-01       Impact factor: 2.011

6.  Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii.

Authors:  Hua Cong; Ernest J Mui; William H Witola; John Sidney; Jeff Alexander; Alessandro Sette; Ajesh Maewal; Rima McLeod
Journal:  Immunome Res       Date:  2010-12-03

7.  Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide.

Authors:  E A Emini; J V Hughes; D S Perlow; J Boger
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

8.  NetMHCpan, a method for MHC class I binding prediction beyond humans.

Authors:  Ilka Hoof; Bjoern Peters; John Sidney; Lasse Eggers Pedersen; Alessandro Sette; Ole Lund; Søren Buus; Morten Nielsen
Journal:  Immunogenetics       Date:  2008-11-12       Impact factor: 2.846

9.  Reliable B cell epitope predictions: impacts of method development and improved benchmarking.

Authors:  Jens Vindahl Kringelum; Claus Lundegaard; Ole Lund; Morten Nielsen
Journal:  PLoS Comput Biol       Date:  2012-12-27       Impact factor: 4.475

10.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007
View more
  11 in total

1.  Antigenic properties of dense granule antigen 12 protein using bioinformatics tools in order to improve vaccine design against Toxoplasma gondii.

Authors:  Ali Dalir Ghaffari; Abdolhossein Dalimi; Fatemeh Ghaffarifar; Majid Pirestani
Journal:  Clin Exp Vaccine Res       Date:  2020-07-31

2.  Determination of B and T Cell Epitopes in Neospora caninum Immune Mapped Protein-1 (IMP-1): Implications in Vaccine Design against Neosporosis.

Authors:  Naser Nazari; Bahareh Kordi; Bahman Maleki; Morteza Shams; Esfandiar Azizi; Hamidreza Majidiani; Razi Naserifar
Journal:  Biomed Res Int       Date:  2022-04-07       Impact factor: 3.411

3.  Evaluation of immune protection against Toxoplasma gondii infection in mice induced by a multi-antigenic DNA vaccine containing TgGRA24, TgGRA25 and TgMIC6.

Authors:  Xiao-Pei Xu; Wen-Ge Liu; Qian-Ming Xu; Xing-Quan Zhu; Jia Chen
Journal:  Parasite       Date:  2019-09-19       Impact factor: 3.000

Review 4.  Review on the Current Trends of Toxoplasmosis Serodiagnosis in Humans.

Authors:  Rochelle Haidee D Ybañez; Adrian P Ybañez; Yoshifumi Nishikawa
Journal:  Front Cell Infect Microbiol       Date:  2020-05-08       Impact factor: 5.293

5.  In silico analysis and expression of a new chimeric antigen as a vaccine candidate against cutaneous leishmaniasis.

Authors:  Leila Motamedpour; Abdolhossein Dalimi; Majid Pirestani; Fatemeh Ghaffarifar
Journal:  Iran J Basic Med Sci       Date:  2020-11       Impact factor: 2.699

6.  In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19.

Authors:  Hüseyin Can; Ahmet Efe Köseoğlu; Sedef Erkunt Alak; Mervenur Güvendi; Mert Döşkaya; Muhammet Karakavuk; Adnan Yüksel Gürüz; Cemal Ün
Journal:  Sci Rep       Date:  2020-12-28       Impact factor: 4.379

7.  Bioinformatics analysis of calcium-dependent protein kinase 4 (CDPK4) as Toxoplasma gondii vaccine target.

Authors:  Masoud Foroutan; Shahrzad Soltani; Ali Taghipour; Ali Dalir Ghaffari; Hamidreza Majidiani; Mohamad Sabaghan
Journal:  BMC Res Notes       Date:  2021-02-06

8.  Neospora caninum SRS2 Protein: Essential Vaccination Targets and Biochemical Features for Next-Generation Vaccine Design.

Authors:  Ali Asghari; Bahareh Kordi; Bahman Maleki; Hamidreza Majidiani; Morteza Shams; Razi Naserifar
Journal:  Biomed Res Int       Date:  2022-04-06       Impact factor: 3.411

9.  Immunoinformatic analysis of immunogenic B- and T-cell epitopes of MIC4 protein to designing a vaccine candidate against Toxoplasma gondii through an in-silico approach.

Authors:  Ali Dalir Ghaffari; Abdolhossein Dalimi; Fatemeh Ghaffarifar; Majid Pirestani; Hamidreza Majidiani
Journal:  Clin Exp Vaccine Res       Date:  2021-01-31

10.  Toxoplasma gondii Tyrosine-Rich Oocyst Wall Protein: A Closer Look through an In Silico Prism.

Authors:  Ali Asghari; Hamidreza Majidiani; Taher Nemati; Mohammad Fatollahzadeh; Morteza Shams; Razi Naserifar; Bahareh Kordi
Journal:  Biomed Res Int       Date:  2021-10-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.